Adult Brain Tumor Consortium (ABTC)

描述(申请人提供)：本申请响应RFA-CA-08-504，旨在继续支持成人原发性中枢神经系统癌症的1期和2期治疗研究，并继续最初在RFA CA-04-001下资助的活动。目前由两个独立的成人脑瘤联盟：脑瘤治疗新方法(NABTT)和北美脑瘤联盟(NABTC)资助的这一单一、整合的应用程序旨在最大限度地提高临床试验效率并增强对翻译研究的支持。成人脑瘤联合会(ABTC)将通过保留NABTT和NABTC成员机构的大部分以及临床试验、药理学、生物统计学和神经病理学的领导地位，利用在前几个获奖期培育的科学专业知识和经验。ABTC的联合首席调查员(斯图尔特·格罗斯曼和迈克尔·普拉多斯)自1994年成立以来一直指导NABTT和NABTC的活动。ABTC将利用NABTT业务办公室(斯图尔特·格罗斯曼和喜悦·费舍尔)、NABTC生物统计学家(凯瑟琳·拉姆伯恩)、NABTT和NABTC的药剂师(杰夫·苏普科和约翰·库恩)以及神经成像(格雷格·索伦森和莎拉·纳尔逊)和神经病理学(肯·阿尔达佩)专家的技能和经验。根据预先确定的标准，ABTC指导委员会将评估潜在的成员网站，取消表现不佳的成员网站，评估竞争性申请，并奖励药理学、成像和相关生物学研究的资金。ABTC的委员会结构将侧重于与NIH、孢子、合作团体、机构翻译研究、制药公司和新的多学科方法的互动。一个经验丰富和国际化的外部咨询委员会将为ABTC提供宝贵的意见。这个新合并的联盟将努力开发更有效的成人脑瘤疗法，方法是：1)通过进行第1-2期临床试验，安全有效地将新型抗癌药物引入高级别原发脑瘤的治疗；2)积极寻求与NCI资助的其他临床试验机制和研究人员的合作，致力于寻找治疗成人脑瘤的有前景的新方法；以及3)适当地将药代动力学和药效学终点(包括成像和翻译实验室研究)纳入第1-2期研究。

DESCRIPTION (provided by applicant): This application responds to RFA-CA-08-504 which is intended to continue support for Phase 1 and 2 treatment studies in adults with primary central nervous system cancers and to continue the activities that were funded initially under RFA CA-04-001. This single, consolidated application from the two currently funded separate adult brain tumor consortia: New Approaches to Brain Tumor Therapy (NABTT) and North American Brain Tumor Consortium (NABTC) is designed to maximize clinical trial efficiency and enhance support for translational research. The Adult Brain Tumor Consortium (ABTC) will capitalize on the scientific expertise and experience that has been nurtured during the previous award periods by retaining the majority of the NABTT and NABTC member institutions as well as clinical trial, pharmacology, biostatistics, and neuropathology leadership. The Co-Principal Investigators of the ABTC (Stuart Grossman and Michael Prados) have directed the activities of NABTT and NABTC since their inception in 1994. ABTC will utilize the skills and experience of The NABTT Operations Office (Stuart Grossman and Joy Fisher), the NABTC biostatistician (Kathleen Lamborn), pharmacologists from NABTT and NABTC (Jeff Supko and John Kuhn), and neuro-imaging (Greg Sorensen and Sarah Nelson) and neuropathology (Ken Aldape) experts. Based on predetermined criteria, the ABTC Steering Committee will evaluate potential member sites, dismiss underperforming member sites, and evaluate competitive applications and award funds for pharmacologic, imaging, and correlative biology research. ABTC's committee structure will focus on interactions with the NIH, SPOREs, cooperative groups, institutional translational research, pharmaceutical companies, and novel multidisciplinary approaches. An experienced and international External Advisory Board will provide valuable input to ABTC. This newly consolidated consortium will strive to develop more effective therapies for adult brain tumors by: 1) safely and efficiently introducing novel anticancer agents into the treatment of high grade primary brain tumors through the conduct of Phase 1-2 clinical trials, 2) Proactively seeking collaborations with other NCI-funded clinical trials mechanisms and researchers devoted to finding promising new treatment approaches for adult brain tumors; and 3) Incorporating pharmacokinetic and pharmacodynamic endpoints (including imaging and translational laboratory studies) as appropriate into Phase 1-2 studies.